Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.

Trial Profile

Dose-escalating open-label trial to assess the tolerability of IPP 204106 in patients with various cancers, including breast cancer, lung cancer and bladder cancer with at least one treatment failure.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Oct 2012

At a glance

  • Drugs IPP 204106 (Primary)
  • Indications Bladder cancer; Breast cancer; Cancer; Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Oct 2012 Status changed from recruiting to completed, according to an ImmuPharma media release.
    • 06 Dec 2010 New trial record
    • 19 Nov 2010 Brief preliminary results have been reported in an ImmuPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top